US FDA Requires Warning on Weight-Loss Drugs for Vision Loss Risk
Translated & summarized from Ice by baba
The U.S. FDA has ordered manufacturers of popular weight-loss drugs like Ozempic and Wegovy to add warnings about a potential risk of vision loss due to NAION. This follows a surge in usage, with millions of people in the U.S. and record demand in Israel. While the risk is considered statistically low and pre-existing conditions complicate causality, hundreds of lawsuits have been filed. Medical experts stress that the drugs' proven benefits outweigh the minimal risk, but advise immediate medical attention for any vision changes.
The story in 5 lines · by baba
- The FDA is requiring new warnings on weight-loss drugs like Ozempic for potential vision loss risk.
- The condition, NAION, involves reduced blood supply to the optic nerve, potentially causing permanent vision loss.
- Millions use these drugs in the U.S., with record demand and shortages also reported in Israel.
- Hundreds of lawsuits allege inadequate warnings from manufacturers Novo Nordisk and Eli Lilly.
- Medical experts state the drugs' benefits outweigh the minimal risk, but advise seeing a doctor for vision changes.
The U.S. Food and Drug Administration (FDA) has mandated that manufacturers of GLP-1 and GIP/GLP-1 class drugs, including popular medications like Ozempic, Wegovy, Mounjaro, and Zepbound, update their consumer warning labels. This action addresses a potential risk of developing NAION (non-arteritic anterior ischemic optic neuropathy), a condition that causes a sharp reduction in blood supply to the optic nerve and can lead to permanent vision loss.
The demand comes amid a global pharmaceutical revolution, with approximately 12% of U.S. adults currently using these drugs, and nearly one in five having tried them. Israel is also experiencing record demand, leading to recurring shortages. When a statistically rare side effect affects tens of millions, it translates into a significant number of actual cases and widespread public concern.
NAION, sometimes called a "stroke of the optic nerve," typically manifests as a sudden, one-sided decrease in vision, blurriness, or a blind spot in one eye, often without pain. While alarming, data from an FDA review of 126 clinical trials involving over 134,000 participants found only 10 probable cases among drug recipients compared to 5 in the control group, indicating a low incidence rate. Furthermore, pre-existing risk factors for NAION, such as diabetes, high blood pressure, and sleep apnea, are common among patients using these medications, complicating the establishment of a direct causal link.
In parallel with the FDA's decision, nearly 300 lawsuits have been filed in the U.S. against Novo Nordisk and Eli Lilly, alleging inadequate warnings. The companies maintain that the data does not establish a causal link and that the warning is a broad, categorical measure. Medical professionals emphasize that patients should not stop taking these medications on their own, as the proven health benefits, including prevention of heart attacks, strokes, death, and kidney disease, significantly outweigh the minimal risk. However, any sudden vision changes or blurriness warrant immediate consultation with an eye doctor.
Separately, Israel's Ministry of Health recently issued a warning against the purchase and use of illegal peptides marketed for weight loss, bodybuilding, and athletic performance enhancement, citing severe health risks due to their unapproved and unsupervised nature.
